JPMorgan Chase & Co. 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-09 1:17 pm Sale | 2024-03-29 | 13G | PMV Pharmaceuticals, Inc. PMVP | JPMORGAN CHASE & CO JPM | 15,573 0.000% | -3,659,241 (-99.58%) | Filing |
| 2024-01-23 09:40 am Sale | 2023-12-29 | 13G | PMV Pharmaceuticals, Inc. PMVP | JPMORGAN CHASE & CO JPM | 3,674,814 7.100% | -329,953 (-8.24%) | Filing |
| 2023-01-25 12:18 pm Sale | 2022-12-30 | 13G | PMV Pharmaceuticals, Inc. PMVP | JPMORGAN CHASE & CO JPM | 4,004,767 8.700% | -580,692 (-12.66%) | Filing |
| 2022-07-07 10:06 am Purchase | 2022-06-30 | 13G | PMV Pharmaceuticals, Inc. PMVP | JPMORGAN CHASE & CO JPM | 4,585,459 10.000% | 1,419,009 (+44.81%) | Filing |
| 2022-01-26 11:54 am Purchase | 2021-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP | JPMORGAN CHASE & CO JPM | 3,166,450 6.900% | 3,166,450 (New Position) | Filing |